Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer

By Gordon N.   Silverman P.   Lasheen W.   Meinert J.   Siminoff L.  

Breast Cancer Research and Treatment, Vol. 102, Iss. 3, 2007-05 ,pp. : 301-312

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic variables in node-negative and node-positive breast cancer - Introduction

By Gasparini G.  

Breast Cancer Research and Treatment, Vol. 51, Iss. 3, 1998-10 ,pp. : 193-194

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant anthracycline therapy as a prognostic factor in metastatic breast cancer

By Alba E.   Ribelles N.   Sevilla I.   Rueda A.   Alonso L.   Marquez A.   Ruiz I.   Miramón J.  

Breast Cancer Research and Treatment, Vol. 66, Iss. 1, 2001-03 ,pp. : 33-39

Springer Publishing Company

Access to resources Recommend Favorite

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

By Eiermann W.   Rezai M.   Kmmel S.   Khn T.   Warm M.   Friedrichs K.   Schneeweiss A.   Markmann S.   Eggemann H.   Hilfrich J.   Jackisch C.   Witzel I.   Eidtmann H.   Bachinger A.   Hell S.   Blohmer J.  

Annals of Oncology, Vol. 24, Iss. 3, 2013-03 ,pp. : 618-624

Oxford University Press

Access to resources Recommend Favorite

Survival in 12,653 breast cancer patients with extensive axillary lymph node metastasis in the anthracycline era

By Beal Shannon  

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1420-1424

Humana Press, Inc

Access to resources Recommend Favorite